Gilead Sciences (NASDAQ: GILD) — Company Overview, News & Financial Data
Gilead Sciences (NASDAQ:GILD) develops innovative biopharmaceuticals focusing on HIV/AIDS, liver diseases, and oncology therapies.
Gilead Sciences
Gilead Sciences is an American biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company's primary therapeutic focus areas include virology, oncology, and inflammation. Its product portfolio features antiviral therapies for the treatment and prevention of human immunodeficiency virus (HIV), viral hepatitis B and C, and COVID-19, alongside targeted cell therapies and oncology treatments for complex cancers. Headquartered in Foster City, California, Gilead operates clinical research and commercial facilities globally, advancing research programs to improve patient care and expand treatment access across international markets.
Snapshot
Operations
Products and/or services of Gilead Sciences
- HIV Antiretroviral Therapies: Portfolio of single-tablet and combination antiviral regimens including Biktarvy, Descovy, and Genvoya. These therapies provide complete treatment and pre-exposure prophylaxis for millions of individuals living with or at risk of human immunodeficiency virus globally.
- COVID-19 Antiviral Treatments: Intravenous nucleotide analog treatments, primarily Veklury (remdesivir), administered to pediatric and adult patients. Used across global hospital systems and outpatient facilities for early and severe viral infection management.
- Viral Hepatitis Medicines: Direct-acting antiviral drug formulations including Epclusa, Harvoni, Sovaldi, and Vemlidy. These oral regimens target chronic hepatitis B and C viral infections to prevent liver damage, cirrhosis, and hepatic carcinoma.
- Oncology and Antibody-Drug Conjugates: Target-directed biopharmaceutical therapies led by Trodelvy (sacituzumab govitecan-hziy). Designed to treat unresectable locally advanced or metastatic triple-negative breast cancer, HR-positive/HER2-negative breast cancer, and metastatic urothelial carcinomas.
- Chimeric Antigen Receptor T-Cell Therapies: Autologous cell therapy manufacturing and treatment platforms including Yescarta and Tecartus. Engineered to target CD19 receptors for treating relapsed or refractory large B-cell lymphoma and mantle cell lymphoma.
- Inflammatory and Liver Disease Pipeline: Clinical research and development programs focusing on targeted small molecules and biologics. Designed to address underserved indications including primary biliary cholangitis, ulcerative colitis, Crohn's disease, and advanced liver inflammation.
Gilead Sciences executive team
- Mr. Daniel P. O'DayChairman & CEO
- Mr. Andrew D. DickinsonChief Financial Officer
- Ms. Johanna MercierChief Commercial & Corporate Affairs Officer
- Ms. Erin BurkhartSVP, Controller & Principal Accounting Officer
- Ms. Jacquie Ross C.F.A.Senior Vice President of Treasury and Investor Relations
- Ms. Keeley WettanExecutive VP and General Counsel of Legal & Compliance
- Ms. Jyoti K. MehraExecutive Vice President of Human Resources
- Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio
- Dr. Flavius Martin M.D.Executive Vice President of Research
- Ms. Janet DorlingSenior Vice President of Intercontinental Region & Global Patient Solutions